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There is limited insight into the mechanisms involved in the counterregulation of TLR.
Given the important role of TLR3/TIR domain-containing adaptor-inducing IFN-b (TRIF)-
dependent signalling in innate immunity, novel insights into its modulation is of signifi-
cance in the context of many physiological and pathological processes. Herein, we sought
to perform analysis to definitively assign a mechanistic role for MyD88 adaptor-like (Mal),
an activator of TLR2/4 signalling, in the negative regulation of TLR3/TRIF signalling.
Biochemical and functional analysis demonstrates that Mal negatively regulates TLR3, but
not TLR4, mediated IFN-b production. Co-immunoprecipitation experiments demonstrate
that Mal associates with IRF7 (IRF, IFN regulatory factor), not IRF3, and Mal specifically
blocks IRF7 activation. In doing so, Mal impedes TLR3 ligand-induced IFN-b induction.
Interestingly, Mal does not affect the induction of IL-6 and TNF-a upon TLR3 ligand
engagement. Together, these data show that the TLR adaptor Mal interacts with IRF7 and,
in doing so, impairs IFN-b induction through the positive regulatory domains I-III
enhancer element of the IFN-b gene following poly(I:C) stimulation. Our findings offer a
new mechanistic insight into TLR3/TRIF signalling through a hitherto unknown
mechanism whereby Mal inhibits poly(I:C)-induced IRF7 activation and concomitant IFN-b
production. Thus, Mal is essential in restricting TLR3 signalling thereby protecting the
host from unwanted immunopathologies associated with excessive IFN-b production.
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Introduction
TLR are important participants in the first line of defense against
invading pathogens [1, 2]. Upon ligand activation of the TLR,
cytosolic Toll/IL-1 receptor (TIR) domain-containing adaptor
proteins are recruited [1], of which, four activating adaptors have
been identified, Myeloid differentiation factor 88 (MyD88),
MyD88 adaptor-like (Mal)/Toll-IL-1 adaptor protein (TIRAP),
TIR domain-containing adaptor-inducing IFN-b (TRIF) and TRIF-
related adaptor molecule (TRAM). Despite the TLR having
somewhat similar signal transduction pathways, there is specifi-
city with regard to their adaptor usage [3]. MyD88 is the common
downstream adaptor that is recruited by all TLR except TLR3 [4].
Mal is required for signalling by TLR4 and TLR2 [5], though it
has recently been reported that Mal is not essential for TLR2
signalling [6]. TRIF mediates TLR3 and TLR4 signalling and is
involved in the activation of the transcription factors IRF3 (IRF,
IFN regulatory factor) and IRF7 and consequential expression of
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Type I IFN [7]. Finally, TRAM mediates TLR4 signalling
exclusively [7] acting as a bridging adapter to recruit TRIF to
the TLR4 complex. Regarding Mal, studies have shown that Mal
interacts with MyD88, TRIF and TRAM [7, 8], but not SARM
(data not shown). Although the adaptors are believed to
participate in the activation of TLR signalling cascades, a number
of recent studies highlight the role of TLR adaptors in the
negative regulation of alternative TLR [6, 9].
Regarding the IFN-b gene itself, transcriptional activation
requires assembly of a multiprotein complex to form the IFN-b
‘‘enhanceosome’’ [10] which is divided into four positive regulatory
domains (PRD) whereby ATF-2/c-Jun binds to the PRDIV element
within the IFN-b enhancer region and is activated by JNK. IRF3 and
IRF7 are activated by ligand-mediated phosphorylation upon which
they are rapidly translocated to the nucleus where they bind the
PRDI-III enhancer element within the IFN-b promoter [10]. Using
gene-targeted mice, recent studies have shown that both IRF3 and
IRF7 play essential roles in Type I IFN-b expression [11, 12].
Regarding NF-kB (p50:RelA), phosphorylated NF-kB translocates
to the nucleus where it binds to the PRDII element within the IFN-b
enhancer [10]; the role of p50, RelA and c-Rel in IFN-b gene
induction is relatively minor [13]. Taken together, these studies
suggest that IRF are the master regulators of IFN-b gene induction
and that NF-kB plays a relatively minor role.
Understanding how pro-inflammatory TLR adaptors can modu-
late non-cognate TLR in certain situations has many implications,
not the least of which is a comprehensive understanding of the
interplay between various TLR that are likely activated during
microbial infections. Although the ability of TLR adaptors to activate
specific signalling pathways has been well defined, the ability to
negatively regulate non-cognate TLR signalling cascades requires
further investigation [9, 13]. Recently, it has been shown that
MyD88 negatively regulates TLR3/TRIF-induced corneal inflamma-
tion [9]. Also, potentiation of poly(I:C)-mediated IL-6 induction and
JNK phosphorylation was observed in Mal/ BM-derived macro-
phages (BMDM) when compared with WT BMDM [6]. Herein, we
provide the first detailed mechanistic analysis of how TLR signalling
may be counterregulated by non-canonical mechanisms.
Results
Poly(I:C)-induced IFN-b induction is exacerbated in the
absence of Mal
As shown in Fig. 1A, following quantitative real-time RT-PCR
measurements, we demonstrate that although stimulation of WT
BMDM, expressing TLR3 endosomally [14], with poly(I:C)
resulted in IFN-b gene induction, a significantly greater induction
of IFN-bwas evident in Mal/ BMDM. In contrast to poly(I:C), we
found comparable levels of IFN-b induction in WT and Mal-
deficient BMDM stimulated with the TLR7 ligand, R848 and the
TLR9 ligand, CpG (Supporting Information Fig. 1). Correlating
with numerous studies showing that TRIF is essential for TLR3-
mediated IFN-b gene induction [15–17], this study shows that
poly(I:C) mediates IFN-b gene induction in murine macrophages is
TRIF-dependent and hence implicates TLR3 in the mediation of
poly(I:C)-mediated IFN-b gene induction. We also demonstrate
that although TNF-a gene induction was not significantly different
in Mal/ cells when compared with WT cells following poly(I:C)
stimulation, a significant decrease in LPS-mediated TNF-a gene
induction was evident (Fig. 1B). Next, we sought to investigate the
role of Mal in the translational regulation of IFN-b and TNF-a by
ELISA. As shown in Fig. 1C, we show that although stimulation of
WT BMDM with poly(I:C) resulted in IFN-b induction, a
significantly greater induction of IFN-b was evident in Mal/
BMDM. Correlating with real-time PCR data and the previous
reports [16–18], LPS and poly(I:C)-induced IFN-b production was
significantly decreased in TRIF-deficient BMDM when compared
with WT BMDM (Fig. 1C). In accordance with the previous studies
showing that Mal P125H and the TIRAP inhibitory peptide block
LPS induced IFN-b gene induction [15, 19], we show that LPS-
induced IFN-b production was significantly decreased in Mal-
deficient BMDM when compared with WT BMDM (Fig. 1C). We
also show that TNF-a and IL-6 induction were not significantly
different in Mal/ cells when compared with WT cells following
poly(I:C) stimulation (Fig. 1E and F). As expected, we demon-
strate an impairment of TNF-a and IL-6 induction in Mal- and
TRIF-deficient BMDM cells stimulated with LPS (Fig. 1E and F). To
rule out the possibility that enhanced IFN-b in Mal/ cells may be
attributed to the BMDM immortalisation procedure per se, ex vivo
BMDM from WT and Mal/ mice were stimulated with either
poly(I:C) or LPS and cytokines were measured by ELISA. Similar to
data generated using the immortalised BMDM, poly(I:C)-induced
IFN-b production was significantly enhanced in Mal-deficient
BMDM when compared with WT BMDM (Fig. 1D). We also show
that treatment of BMDMwith a Mal inhibitory peptide significantly
augmented poly(I:C)-mediated IFN-b gene induction when
compared with cells treated with the control-inhibitory peptide
(Fig. 1G). Furthermore, C57BL/6, Mal-deficient and TRIF-deficient
BMDM did not exhibit differences in TLR3 mRNA receptor
expression, indicating that reported differences in gene induction
are not attributable to perturbations in TLR3 expression levels
(Table 1). Contrary to the previous reports [20], the data
presented herein demonstrate that poly(I:C)-mediated induction
of IFN-b in murine macrophages is TLR3 dependent, as TRIF, the
critical adaptor involved in TLR3 signal transduction, is essential
for poly(I:C)-mediated IFN-b induction. Also, correlating with the
previous reports [21] poly(I:C)-mediated induction of IFN-b,
CCL5/Rantes and TNF-a was similar in WT and MAVS/ BMDM
(Supporting Information Fig. 2), suggesting that the TLR and
retinoic acid-inducible gene-I-like receptor (RLR) pathways work
in parallel to sense viruses. The data presented herein correlate
with numerous previous studies, demonstrating that TLR3/TRIF
are essential for poly(I:C)-induced IFN-b production in certain cell
types [15–17]. Also, in a germline TLR3 mutation identified in
humans [22], impaired responses to poly(I:C) including IFN-b
production were evident, adding further credence to the hypoth-
esis that TLR3 is essential for poly(I:C)-mediated IFN-b production
in vivo. Though poly(I:C) has been shown to activate TLR3-
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independent pathways involving the RLR in GM-CSF-DC [20, 23],
our study clearly shows that in macrophages, poly(I:C) mediates
its effects through a TLR3/TRIF-dependent pathway; the apparent
discrepancies may be attributed to differences in cell type chosen
for study. Importantly, our data clearly demonstrate that although
Mal does not affect TLR3-induced pro-inflammatory cytokine
production, Mal has a negative regulatory effect on TLR3-induced
IFN-b gene induction and IFN-b production.
Next, the ability of Mal to negatively regulate IFN-b gene
induction in two human cells lines of relevance to TLR3 signalling
namely lung bronchial epithelial BEAS-2B cells, known to express
TLR3 on the cell surface and intracellularly [24], and macrophage-
like differentiated THP-1 cells was investigated. We demonstrate
that treatment of BEAS-2B cells with a Mal-inhibitory peptide
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Figure 1. Poly(I:C)-induced IFN-b induction is exacerbated in the absence of Mal. BMDM from WT, Mal/ and TRIF/ mice were treated with
poly(I:C) (1 mg/mL) or LPS (10 ng/mL) for 4 or 16 h. (A, B) Immortalised BMDM treated for 4 h. Quantitative real-time PCR was used to assay the
expression levels of (A) IFN-b and (B) TNF-a. (C) Immortalised and (D) primary BMDM were treated for (C) 4 h and (D) 16 h and IFN-b levels were
measured by ELISA. (E, F) Immortalised BMDM were treated for 4 and 16 h. Thereafter, (E) TNF-a and (F) IL-6 levels were measured by ELISA. (G) WT
immortalised BMDM were pretreated with a Mal inhibitory or control peptide (20 mM) for 1 h. Thereafter, cells were stimulated with poly(I:C) for 4 h
followed by quantitative real-time RT-PCR to assay the expression levels of IFN-b. The results presented are compiled from at least three
independent experiments, each experiment being performed in triplicate (mean7SE). po0.005 (unpaired Student’s t-test).
Table 1. Analysis of TLR3 expression in BMDM cell linesa)
D CT (C(T)TLR3-C(T)HPRT)
Unstim. Poly(I:C)
BMDM WT 4.97770.182 3.47970.538
BMDM Mal/ 4.91070.040 3.75370.604
BMDM TRIF/ 4.36770.273 3.62270.486
a) Immortalized BMDM from WT, Mal/ and TRIF/ mice were
untreated or treated with poly(I:C) (1 mg/mL) for 90 min. Thereafter,
real-time PCR was performed using oligonucleotides specific for the
amplification of either TLR3 or HPRT. Relative expression of TLR3
was assessed as described. The results presented are the mean7SE
of triplicates from three independent experiments (mean7SE).
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significantly enhanced TLR3-ligand-induced IFN-b when compared
with cells treated with control peptide (Fig. 2A) and TNF-a gene
induction remained unaffected (Fig. 2B). Moreover, treatment of
BEAS-2B cells with the Mal inhibitory peptide enhanced poly(I:C)-
induced IFN-b production (Fig. 2C) and suppression of Mal
expression significantly enhanced poly(I:C)-induced IFN-b in THP1
cells (Fig. 2D). Taken together, these data show that suppression of
Mal augments TLR3-mediated IFN-b induction in human macro-
phages and human bronchial epithelial cells.
TLR3/TRIF-induced IFN-b gene expression
is negatively regulated by Mal via PRDI-III
To investigate the ability of Mal to modulate IFN-b induction at
the transcriptional level, we used the NF-kB, IFN-b, PRDIV and
PRDI-III luciferase reporter gene constructs. Correlating with the
previous reports [25], we found that transfection of HEK293-
TLR3 cells, known to express cell-surface TLR3 [26], with the
dominant negative TRIF (TRIF-DN) inhibited poly(I:C)-induced
activation of the IFN-b reporter gene (Fig. 3A). Interestingly, we
found that although transfection of HEK293-TLR3 cells with Mal
or the TIR domain of Mal inhibited the poly(I:C)-induced
activation of the IFN-b reporter gene, the N-terminal region of
Mal did not inhibit, but rather, augmented poly(I:C)-mediated
activation of the IFN-b reporter activity (Fig. 3A). We also found
that although TRIF-DN inhibited the poly(I:C)-induced activation
of the NF-kB reporter gene, Mal was without effect (Fig. 3D). We
also found that although TRIF-DN inhibited poly(I:C)-induced
activation of the PRDIV reporter gene, Mal and its variants did
not inhibit PRDIV reporter activity (Fig. 3B). Interestingly, we
found that Mal and the TIR domain of Mal inhibited poly(I:C)-
induced activation of the PRDI-III reporter gene (Fig. 3C).
Collectively, these data clearly demonstrate that Mal modulates
IFN-b gene induction whereby the TIR domain of Mal inhibits the
PRDI-III reporter gene.
Given that TRIF is essential for poly(I:C)-mediated signalling via
TLR3 [17], we tested the ability of Mal to modulate TRIF-dependent
gene induction. Correlating with the previous reports [25], ectopic
expression of TRIF potently activated the IFN-b reporter gene
(Fig. 4A). We found that although ectopic expression of Mal or the
TIR domain of Mal dose-dependently inhibited TRIF-induced acti-
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Figure 2. Suppression of Mal enhances IFN-b induction by TLR3. (A–C) BEAS-2B cells were pretreated with a Mal inhibitory or control peptide (20mM)
for 1 h. Thereafter, cells were stimulated with poly(I:C) (10mg/mL) for (A, B) 1.5 and 3 h and (C) 16 h. (A, B) Quantitative real-time RT-PCR was performed
to assay the expression levels of (A) IFN-b and (B) TNF-a. (C) IFN-b levels were measured by ELISA. (D) THP1 cells were transduced with lentiviral
particles encoding either Mal shRNA or control empty vector. After treatment for 4 wk with puromycin, cells were differentiated to macrophage-like
cells using CSF and stimulated with poly(I:C) (10mg/mL) for 3 h. Quantitative real-time RT-PCR was performed to assay the expression levels of IFN-b.
Basal Mal mRNA expression in unstimulated cells is shown in the inset (quantitative real-time PCR); HPRT serves as a control. The data presented are
compiled from at least three independent experiments, each experiment being performed in triplicate (mean7SE). po0.05, po0.005 (unpaired
Student’s t-test).
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vation of the IFN-b reporter gene, the N-terminal region of Mal did
not inhibit, but rather, augmented IFN-b reporter gene activity (Fig.
4A). Further, we found that Mal-TIR inhibited the induction of the
IFN-b reporter gene by Mal-N-terminal. As a control, we found that
the TLR adaptor TRAM did not inhibit TRIF-induced activation of the
IFN-b reporter gene (Fig. 4A). To preclude the possibility that Mal
may exert its effects through poly(I:C)-mediated activation of the
RLR, retinoic acid-inducible gene I (RIG-I) or melanoma differ-
entiation-associated antigen 5 (Mda-5), rather than through TLR3/
TRIF, cells were co-transfected with a plasmid encoding either RIG-I
or Mda-5 and increasing amounts of Mal. Although ectopic expres-
sion of RIG-I and Mda-5 activated the IFN-b reporter gene, Mal did
not inhibit, but rather augmented RIG-I/Mda-5-mediated IFN-b
reporter gene activity (Fig. 4E). As expected, although TRIF activated
the NF-kB and the PRDIV reporter genes (Fig. 4B and C), Mal and its
variants did not inhibit TRIF-induced activation of the NF-kB
(Fig. 4B) and PRDIV reporter genes (Fig. 4C). Also, although Mal
and the TIR domain of Mal inhibited TRIF-induced activation of the
PRDI-III reporter gene (Fig. 4D), the N-terminal region of Mal did
not (Fig. 4D). Taken together, these data clearly demonstrate that
Mal modulates TRIF-mediated IFN-b gene induction whereby the
TIR domain of Mal inhibits the TRIF-induced activation of the PRDI-
III reporter gene. Moreover, the inhibitory role of Mal in poly(I:C)-
mediated induction of IFN-b is TLR3/TRIF dependent and involves
the PRDI-III enhancer element of the IFN-b promoter.
Mal negatively regulates TRIF:IRF7, but not TRIF:IRF3-
mediated activation of the IFN-b reporter gene
Given that the data presented thus far provide compelling evidence
that Mal negatively regulates IFN-b induction by blocking the PRDI-
III element, we sought to establish whether this effect was mediated
through IRF3 or IRF7. To this end, we transfected HEK293 cells
with either the IFN-b or the PRDI-III luciferase reporter constructs
and plasmids encoding either IRF3 or IRF7. Given that both IRF are
weak activators of the IFN-b promoter [27], we opted to co-
transfect the cells with TRIF (10ng) to enhance the signal output
and to aid in the engagement of auxiliary molecules necessary for
IFN-b and PRDI-III gene induction. In addition, cells were co-
transfected with increasing amounts of Mal, Mal-TIR or N-Mal. We
demonstrate that ectopic expression of IRF7, but not IRF3, potently
activated the IFN-b reporter gene and the PRDI-III enhancer
element of the IFN-b reporter gene (Fig. 5A–D); this effect was
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Figure 3. TLR3-mediated IFN-b gene expression is negatively regulated by Mal via PRDI-III. (A–C) HEK293-TLR3 cells were co-transfected with the
(A) IFN-b dependent, (B) IFN-b PRDIV or (C) IFN-b PRDI-III reporter gene constructs (80 ng) and the empty vector (100 ng) or increasing amounts (10,
20, 50 and 100 ng) of the expression vectors encoding TRIF-DN, Mal, Mal-TIR or Mal-N-terminal. After 16 h, the cells were treated with poly(I:C)
(10 mg/mL) for 6 h. The cells were then harvested and luciferase reporter gene activity in the cell lysates assessed. In addition, expression of TRIF-
DN, Mal and its variants was confirmed by western blot analysis. Cells co-transfected with the reporter gene and 100 ng of the indicated empty/
expression vector in the absence of poly(I:C) stimulation (i.e. vehicle alone) served as controls. (D) HEK293-TLR3 cells were co-transfected with the
NF-kB-dependent reporter gene construct and the empty vector (100 ng) or increasing amounts of the expression vectors encoding Mal (10, 25 and
50 ng) or TRIF-DN (10, 25 and 50 ng) and luciferase activity following poly(I:C) stimulation determined as in (A–C). The results presented are
compiled from at least three independent experiments, each experiment being performed in triplicate (mean7SE).
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significantly enhanced by TRIF (Fig. 5A and C). Also, suppression
of IRF7 expression impaired poly(I:C)-mediated IFN-b gene
induction, confirming that IRF7 is involved in poly(I:C)-mediated
induction of IFN-b (data not shown). Interestingly, we demonstrate
that although ectopic expression of Mal or the TIR domain of Mal
dose-dependently inhibited IRF7:TRIF-induced activation of the
IFN-b and PRDI-III reporter genes, the N-terminal region of Mal did
not (Fig. 5A and C). Additionally, Mal did not affect TBK1/IKKe-
induced activation of the IFN-b and PRDI-III reporter genes nor the
IRF3/IRF7 transactivation reporter gene induction (Supporting
Information Fig. 3). We also show that Mal and its variants did not
significantly affect IRF3:TRIF-induced activation of the IFN-b and
PRDI-III reporters (Fig. 5B and D).
Mal inhibits TLR3/TRIF-mediated activation of IRF7
Given that our data suggest that the TIR domain of Mal negatively
regulates TLR3:TRIF:IRF7-induced IFN-b gene induction, we
sought to further explore the mechanism involved. Thus, we
examined the ability of Mal to modulate poly(I:C)-mediated IRF7
phosphorylation and nuclear translocation [28]. We clearly
demonstrate that IRF7 undergoes poly(I:C)-induced phosphoryla-
tion and this effect is blocked by Mal (Fig. 6A). Moreover, poly(I:C)
induced the phosphorylation of endogenous IRF7 to a greater
extent in BMDM lacking Mal (Fig. 6B) and densitometric analysis
revealed that 50% greater phosphorylation of IRF7 was evident
in Mal-deficient cells when compared with WT cells following
poly(I:C) stimulation. On the contrary, equivalent IRF3 phosphor-
ylation is evident in WT and Mal-deficient BMDM following
poly(I:C) stimulation (Fig. 6B, lower). As a further test of the
negative role of Mal on IRF7 activation, we examined the effect of
Mal on the nuclear translocation of IRF7. We demonstrate that
over-expression of Mal blocked poly(I:C)-induced nuclear translo-
cation of IRF7 (Fig. 6E). As expected, Mal did not affect the nuclear
translocation of IRF3 following ligand stimulation (Fig. 6E). We
also show that Mal colocalises with IRF7, not IRF3 within the
cytosol of HEK293:TLR3 cells (Supporting Information Fig. 4).
Together, these data show that Mal inhibits IRF7, but not IRF3,
functionality and concomitant IFN-b gene induction. Given that
previous studies show an interaction between IRF and Mal [27], we
hypothesised that Mal may be directly binding to IRF7 and thus
prevent its phosphorylation and translocation. We found that full-
length Mal co-immunoprecipitates with IRF7, but not IRF3 (Fig. 6C
and D). Further, co-immunoprecipitation experiments show that
the TIR-domain of Mal, but not the N-terminal domain of Mal, co-
immunoprecipitates with IRF7, but not with IRF3 (Supporting
Information Fig. 5) and supports the hypothesis that Mal impacts
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Figure 4. Mal negatively regulates TRIF-induced activation of IFN-b and PRDI-III, but not NF-kB or PRDIV, gene induction. (A–D) HEK293 cells were
co-transfected with the full-length IFN-b (A), NF-kB (B), IFN-b PRD IV (C) or the IFN-b PRD I-III (D) reporter gene constructs (80 ng), the empty or
TRIF-encoding vector (20 ng) and increasing amounts (1, 10 and 20 ng) of each of the expression vectors encoding Mal, Mal-TIR, Mal-N-terminal,
Mal-TIR1Mal-N-terminal and TRAM. Cells co-transfected with the reporter gene and 20 ng of the indicated empty/expression vector served as
controls. After 24 h, the cells were harvested and luciferase reporter gene activity in the cell lysates assessed. (E) HEK293 cells were co-transfected
with the full-length IFN-b reporter gene construct and 20 ng of either a vector encoding Mal, RIG-I or Mda-5 or an empty vector and increasing
amounts (1, 10 and 20 ng) of Mal. The cells were stimulated with poly(I:C) (50 mg/mL) for 8 h before assessment of luciferase reporter gene activity in
the cell lysates. The results presented are compiled from at least three independent experiments, each experiment being performed in triplicate
(mean7SE).
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on TLR3:IRF7, not TLR3:IRF3-mediated IFN-b induction. Together,
these data unequivocally demonstrate that Mal negatively regulates
IFN-b induction by binding to IRF7 and blocking its downstream
phosphorylation and translocation of IRF7 to the nucleus.
Discussion
This study sought to explore the mechanism(s) by which the
adaptor Mal negatively regulates TLR3 signalling and whether
Mal has the ability to differentially regulate various signals
emanating from TLR3. Our study demonstrates that comparable
IL-6 and TNF-a induction were evident in Mal-deficient cells and
WT cells following stimulation with the TLR ligand, poly(I:C). On
the contrary, we show for the first time that Type I IFN-b gene
induction is significantly enhanced in Mal-deficient cells, follow-
ing poly(I:C) stimulation and following treatment of cells with
the Mal-inhibitory peptide. Interestingly, we found that full-
length Mal and the TIR-domain of Mal inhibited poly(I:C)/TRIF-
mediated IFN-b and PRDI-III reporter gene activity and this effect
was mediated through IRF7, not IRF3. Moreover, we found that
although Mal inhibited poly(I:C)-mediated IRF7 phosphorylation
and translocation, Mal did not impair poly(I:C)-mediated IRF3
activity. Further, we show that Mal and Mal-TIR interact directly
with IRF7, not IRF3. On the contrary, Mal-N-terminal does not
interact with IRF3 or IRF7. Despite this, Mal-N-terminal drives
IFN-b reporter gene activity via IRF7, though the mechanism
remains elusive. Together, these data describe the target
specificity of the TIR domain of Mal toward the modulation of
poly(I:C)-mediated IRF7 activation whereby Mal interacts with
IRF7 and hence impairs the phosphorylation and nuclear
translocation of IRF7 and concomitant IFN-b gene induction.
Moreover, our study shows that the inhibitory function of Mal is
specific for TLR3, but not TLR7 or TLR9. Given that our data
clearly show that Mal interacts with IRF7 and that a previous
study has shown that TRIF (a TLR3, not TLR7/9, adaptor) also
interacts with IRF7 [27], it is plausible to speculate that there
may be interplay between Mal and TRIF to regulate IRF7
functionality. Regarding the subcellular localisation of Mal itself,
it has been shown that although Mal concentrates at membrane
ruffles in macrophages, Mal-positive intracellular vesicles are also
present throughout the cell [29] to allow shuttling of Mal
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Figure 5. Mal negatively regulates TRIF:IRF7, but not TRIF:IRF3, mediated activation of the IFN-b reporter gene. HEK293 cells were co-transfected
with the (A, B) IFN-b-dependent reporter gene construct or the (C, D) IFN-b PRD I-III reporter gene construct and 10 ng of either TRIF, IRF7, IRF3 or
empty vector and increasing amounts (1, 10 and 20 ng) of the expression vectors encoding Mal, Mal-TIR or Mal-N-terminal as indicated. After 24 h,
the cells were harvested and luciferase reporter gene activity in the cell lysates was assessed. The results presented are compiled from at least
three independent experiments, each experiment being performed in triplicate (mean7SE).
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between the intracellular vesicles and the plasma membrane and
this shuttling event may facilitate Mal:IRF7 interaction. Studies
are ongoing in our lab to further examine the dynamics of this
process at the endogenous level and the molecular architecture
thereof. Nonetheless, impaired IRF7 functionality is evident as a
consequence of Mal following TLR3 ligand engagement.
Type I IFN are one of the early mediators of the innate immune
response and influence the adaptive immune response through
direct and indirect actions on DC, T and B cells, and natural killer
cells. Thus, Type I IFN, including IFN-b, could affect the initiation
and/or amplification of autoimmunity and tissue damage through
their diverse roles in immunity [30]. Notably, upregulation of IFN-
induced genes has been observed in the peripheral blood of patient
subsets with autoimmune diseases such as systemic lupus erythe-
matosus, type I diabetes mellitus and rheumatoid arthritis,
suggesting that an activated IFN gene expression profile is a
common hallmark of certain chronic autoimmune diseases [30].
Thus, it is clearly evident that the ability to curtail excessive/
unwanted IFN-b production is critical to the maintenance of innate
immune stability. Herein, we have identified a novel role for Mal in
innate immunity whereby it serves to curtail the inappropriate
over-production of IFN-b thereby protecting the host from
unwanted immunopathologies associated with its excessive acti-
vation, while maintaining pro-inflammatory cytokine production.
Although Mal bifurcates between TLR4 and TLR3, whereby Mal
activates TLR4 signalling at the plasma membrane [6, 31] and
suppresses endosomally localised TLR3 signalling, the question
arises as to why Mal exerts functionally disparate effects on different
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Figure 6. Mal inhibits TLR3-mediated activation of IRF7. (A, C, D) HEK293-TLR3 cells were co-transfected with vectors encoding IRF7, Mal-HA, IRF7-
Flag, IRF3-Flag or empty vector as indicated. After 24 h, cells were either stimulated with poly(I:C) (25 mg/mL) for 90 min or left unstimulated and
immunoprecipitations (IP) using anti-IRF7, anti-HA or anti-Flag antibodies or IgG as a control performed. The immunoprecipitate was analysed by
western blotting to detect the indicated phosphorylated, tagged or total amount of protein. Following co-transfection and stimulation, whole cell
lysates were also analysed by immunoblotting to confirm the equal expression of the indicated proteins. The results presented are representative
of at least three independent experiments. (B) WT and Mal–/– BMDM were stimulated with poly(I:C) (25 mg/ml) for 90 min or left unstimulated and IP
using anti-IRF7 or IgG as a control performed. The immunoprecipitate was analysed by western blotting to detect the indicated phosphorylated or
total amount of IRF7. Whole cell lysates were also analysed by immunoblotting to confirm the equal phosphorylation and expression of IRF3
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TLR. It is well established that Mal is required for TLR4 signalling
[32, 33] whereby Mal directly interacts with the TIR domain of
TLR4 at the plasma membrane [8, 31], serving to recruit MyD88 to
the TLR4 signalling complex and mediate concomitant pro-inflam-
matory cytokine production [32, 33]. Following TLR4 activation, it
has been proposed that TLR4 first induces Mal-MyD88 signalling at
the plasma membrane and TLR4 is then endocytosed and activates
TRAM-TRIF signalling from early endosomes [31]. We have shown
that Mal does not interact directly with TLR3 as evidenced by yeast-
2-hybrid analysis in our laboratory (data not shown) and by co-
immunoprecipitation experiments [7]. Given that Mal interacts with
IRF7, not IRF3, it is plausible to speculate that the interaction
between Mal and IRF7 may physically obstruct the phosphorylation
of IRF7 and concomitant nuclear translocation.
In conclusion, by identifying Mal as a critical negative
regulator of TLR3/TRIF-dependent IFN-b induction, this study
provides an insight into the molecular mechanisms that serve to
regulate TLR3-dependent signal transduction. Critically, our
study identifies Mal as a novel inhibitor of TLR3-mediated IFN-b
gene induction and offers a new therapeutic strategy for the
molecular intervention of certain autoimmune pathologies asso-
ciated with the excessive production of Type I IFN.
Materials and methods
Cell culture and reagents
HEK293, THP1 and BEAS-2B cell lines were purchased from
ECACC. Highly purified protein-free LPS derived from Escherichia
coli strain 011:B4 was used in all treatments. Naked poly(I:C), a
TLR3 activator, was from Invivogen. Control and Mal/TIRAP
inhibitory peptides were from Calbiochem.
Expression vectors/recombinant plasmids
The NF-kB-luciferase reporter construct and Flag-TRIF as
described previously [7]. TRIF-DN was a generous gift from
Akira [25]. The plasmids pcDNA3:Mal-HA, pcDNA3:Mal-TIR-HA
(AA 73–235) and pcDNA3:Mal-N-terminal (AA 1–74) and
pcDNA3:TRIF-HA were from Professor Luke O’Neill (TCD). The
reporter gene plasmids were as described previously [34]. The
IRF7-Flag plasmid was a generous gift from Professor Paul
Moynagh (NUIM). The IRF3 and IRF7-YFP plasmids were a
generous gift from Professor Taniguchi (University of Tokyo).
The RIG-I and Mda-5 mammalian expression plasmids were gifts
from Professor Steve Goodbourn, University of London.
Sources of macrophages
Mal/TIRAP/ and TRIF/ mice were constructed as described
previously [5, 17]. Mal/TIRAP KO and TRIF/ mice were on a
C57BL/6 background. All mice were confirmed as being homo-
zygous mutants by PCR genotyping of DNA. All the animal
protocols used in this study were approved by the Ethical
Committee at the National University of Ireland, Maynooth and
in accordance with the Animals (Scientific Procedures) Act, 1986,
UK. BM-derived macrophages (BMDM) were generated by
differentiation of age- and sex-matched C57BL/6, Mal/ and
TRIF/ mice for 8 days in complete DMEM medium supple-
mented with L929-conditioned supernatants.
Immortalisation of BMDM
Immortalised cell lines from WT, Mal/ and TRIF/ mice were
established by infecting primary BM cells with the J2 recombi-
nant retrovirus as described previously [6, 35, 36]. Cell lines
showed similar patterns of surface receptor expression, activation
markers and cytokine production in response to various TLR
ligands when compared with primary BMDM.
First strand cDNA synthesis
Total RNA was isolated from all types of cells using the TRIzols
Reagent according to the manufacturer’s instructions (Invitro-
gen). Thereafter, total RNA was converted to first strand cDNA as
described previously [37].
Real-time PCR
Total cDNA was used as starting material for real-time RT-PCR
quantitation with DyNAmosHS SYBR Green kit (Finnzymes) on a
real-time PCR system (DNA Engine OPTICONs system; MJ
Research). For the amplification of the specific genes, the
following primers were used; mIFN-b, forward, GGAGATGACG-
GAGAAGATGC, and reverse, CCCAGTGCTGGAGAAATTGT; hIFN-
b, forward, AACTGCAACCTTTCGAAGCC, and reverse,
TGTCGCCTACTACCTGTTGTGC; mTNFa, forward, CATCTTCT-
CAAAATTCGAGTGACAA, and reverse, TGGGAGTAGACAAGGTA-
CAACCC; hTNFa, forward, CACCACTTCGAAACCTGGGA, and
reverse, CACTTCACTGTGCAGGCCAC; mMal/TIRAP, forward,
GCTTCATCCTCCTCCGT, and reverse, TGTGTTGGTGGCGAGGT;
mTLR3, forward, GTGAGTCTGAAGTACCTAAGTC, and reverse,
GAACTGGTAGACAGTTGGAGGT. For each mRNA quantification,
the housekeeping gene hypoxanthine phosphoribosyltransferase
1 (HPRT) was used as a reference point using the following
primers; mHPRT forward, CCCTGAAGTACTCATTATAGT-
CAAGGGCAT, and reverse, GCTTGCTGGTGAAAAGGACCTCTC-
GAAG; hHPRT forward, AGCTTGCTGGTGAAAAGGAC, and
reverse, TTATAGTCAAGGGCATATCC. Real-time PCR data were
analyzed using 2DDCT method as described previously [38].
Lentiviral transduction
Human Mal lentiviral shRNA plasmids were from Sigma-Aldrich
(Mal MISSIONs shRNA). THP1 cells were lentivirally transduced
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with either the control plasmid (pLKO.1-puro, SCH001) or the
plasmid-encoding shRNA specific for Mal/TIRAP (Tirap
MISSIONs shRNA NM_052887, TRC No. TRCN0000005565).
Thereafter, cells were treated with puromycin (10 mg/mL) for
1wk. Lentivirus vector preparation and virus production were as
described previously [39].
Reporter assays
HEK293 and HEK293-TLR3 cells were transfected with the
luciferase reporter gene plasmids as described previously [7] and
co-transfected with the various expression vectors using Lipofecta-
mine 2000 (Invitrogen). After 24h, cells were stimulated with
stimulated with poly(I:C) as indicated. Thereafter, cell lysates were
prepared and reporter gene activity was measured using the Dual
Luciferase Assay system (Promega) as described previously [40].
Data were expressed as the mean fold induction7SD relative to
control levels, for a representative experiment from a minimum of
three separate experiments, each performed in triplicate.
Transfection and co-immunoprecipitation
HEK293 or HEK293-TLR3 cells were transfected using Lipofecta-
mine 2000 (Invitrogen) with the indicated plasmids. Twenty-four
hours later, cells were stimulated and lysed as described
previously [40]. The immune complexes were precipitated,
washed, eluted by the addition of sample buffer followed by
SDS-PAGE and immunoblotting using the indicated antibodies.
Cytokine analysis
BMDM were stimulated with the indicated ligands. After 4 and
16 h, the cell-free supernatants were removed and analysed for
IFN-b release according to the manufacturer’s (PML) instructions.
IL-6, TNF-a and CCL5 cytokine release were measured as
indicated by the manufacturer (Peprotech).
Immunoblot analysis
Cells were stimulated with ligand as described and lysates were
subjected to SDS-PAGE followed by immunoblot analysis with an
anti-IRF7 (Santa Cruz), anti-phospho-IRF7 (a generous gift from
Professor John Hiscott) anti-IRF3 (Santa Cruz) and anti-phospho-
IRF3 antibodies (Cell Signalling).
Direct immunofluorescence
HEK293-TLR3 cells expressing YFP-tagged IRF3 or IRF7 proteins
were stimulated with poly(I:C) and at appropriate time points,
cells were rinsed with PBS and fixed at RT for 5min with 2%
formaldehyde solution. Cells were counterstained using DAPI
nuclear stain (Sigma). Fluorescence was examined using an
Olympus IX81 fluorescent microscope (Olympus, Germany).
Data analyses
Statistical analysis was carried out using the unpaired Student’s
t-test using SigmaPlot 2001 programme. p-Values of less than or
equal to 0.05 were considered to indicate a statistically significant
difference where  indicated po0.05 and  indicates po0.005.
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